Thymosin alpha-1, explained.
Thymalfasin (Zadaxin). Research, safety questions, and treatment context.
The form
Pharmacy catalog form
The routine
Schedules in hospital studies are not everyday wellness instructions.
The evidence
Human illness studies · everyday benefit uncertain
Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- No lawful route today
No lawful compounding route in the U.S. today. Approved as a drug in several other countries.
- At Goodmorrow
- Not offered
What it is
Thymosin alpha-1 is a 28-amino-acid peptide made by the thymus, the gland that trains immune cells.
What the evidence shows
It has been studied in people for decades, mostly for hepatitis B and C and as an add-on in cancer care and severe infection. The results are mixed, but they exist, which puts it ahead of most peptides sold for wellness.
How Goodmorrow handles it
Not offered today. We'll revisit it if the FDA puts it back on the compounding list.
Questions people ask
Will thymosin alpha-1 come back?
Federal health officials named it in early 2026 as a candidate to return, but it wasn't part of the July 2026 review. There's no date.
Sources
- Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026
- Secondary sourceThe US Peptide Status Index Peptide America
Good days ahead.
Join the opening list for appointment updates.